4 assets in Nut Midline Carcinoma

Therapeutic assets addressing Nut Midline Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Abemaciclib Nut Midline Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Nut Midline Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
ep31670 Nut Midline Carcinoma	Epigenetix, Inc.	P1	CC (43)
mt-4561 Nut Midline Carcinoma	Tanabe Pharma America, Inc.	P1/2	NR ()